Gongwin Biopharm Holdings Co. Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatmen… Read more
Market Cap & Net Worth: Gongwin Biopharm Holdings Co. Ltd. (6617)
Gongwin Biopharm Holdings Co. Ltd. (TWO:6617) has a market capitalization of $293.15 Million (NT$9.70 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #17128 globally and #695 in its home market, demonstrating a -1.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gongwin Biopharm Holdings Co. Ltd.'s stock price NT$79.10 by its total outstanding shares 122620100 (122.62 Million).
Gongwin Biopharm Holdings Co. Ltd. Market Cap History: 2017 to 2026
Gongwin Biopharm Holdings Co. Ltd.'s market capitalization history from 2017 to 2026. Data shows change from $238.23 Million to $293.15 Million (-1.43% CAGR).
Gongwin Biopharm Holdings Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gongwin Biopharm Holdings Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6617 by Market Capitalization
Companies near Gongwin Biopharm Holdings Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Gongwin Biopharm Holdings Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Gongwin Biopharm Holdings Co. Ltd. Historical Marketcap From 2017 to 2026
Between 2017 and today, Gongwin Biopharm Holdings Co. Ltd.'s market cap moved from $238.23 Million to $ 293.15 Million, with a yearly change of -1.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$293.15 Million | -8.13% |
| 2025 | NT$319.09 Million | -24.14% |
| 2024 | NT$420.64 Million | -36.77% |
| 2023 | NT$665.24 Million | -42.38% |
| 2022 | NT$1.15 Billion | +11.05% |
| 2021 | NT$1.04 Billion | +16.39% |
| 2020 | NT$893.17 Million | +201.29% |
| 2019 | NT$296.45 Million | +19.75% |
| 2018 | NT$247.57 Million | +3.92% |
| 2017 | NT$238.23 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Gongwin Biopharm Holdings Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $293.15 Million USD |
| MoneyControl | $293.15 Million USD |
| MarketWatch | $293.15 Million USD |
| marketcap.company | $293.15 Million USD |
| Reuters | $293.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.